000			03063cam a2200349 a 4500
003			EG-GiCUC
005			20250223032508.0
008			191229s2019 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.05.M.Sc.2019.Es.O
100	0		_aEsraa Maged Mohammad
245	1	0	_aOutcome predictors of burkitt{u2019}s lymphoma in children and adolescents : _bA single- institution experience / _cEsraa Maged Mohammad ; Supervised Hanafy Ahmed Hafez , Riham Abdelaziz Khedr , Eman Naguib Khorshed
246	1	5	_aالعوامل المتنبئة بالإستجابة فى سرطان الغدد الليمفاوية فى الأطفال و المراهقين : _bتجربة مؤسسة واحدة
260			_aCairo : _bEsraa Maged Mohammad , _c2019
300			_a102 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aBackground/objective; The outcome of childhood Burkitt{u2019}s lymphoma (BL) has improved steadily over the past decades through the use of intensive sequential multi-agent chemotherapy regimens. This study objective was to assess the outcome predictors of BL in children and adolescents. Methods: A retrospective study included all patients 18 years old or younger diagnosed with BL and treated according to the modified LMB 96 protocol at National Cancer Institute, Cairo university from January 2012 to December 2016 and their follow up till December 2018. Results: A total of 170 patients were diagnosed with BL, with median age of 5 years old. Abdomen was the most common 1ry site (90.0%). Bone marrow involvement was encountered in 7 patients (4%) and 10 (6%) had central nervous system (CNS) disease at presentation. From the whole study cohort, 7 patients (4.1%) were treated as group A, 130 (76.5%) as group B, and 27 (15.9%) patients as group C. The 5 years overall survival (OS) and event free survival (EFS) were 82.9% and 82.8% respectively for the whole group. OS and EFS were 100%, 87.2% and 57.7% for group A, B and C respectively (P<0.001). Significant survival difference due to BM involvement and /or CNS involvement, 50% for (BM+) vs 84.2% for (BM-) (P= 0.026) and 40% for (CNS+) vs 85.8% for (CNS-) (P<0.001). Early initiation of induction cycle in a period {u2264} 10 days of CVP start was associated with better outcome 87.3% vs 68.6% for delayed group >10 days (P=0.020). A total of 39 deaths were reported, about 50% of them were defined as early deaths before 2nd induction and 11 patients died due to disease progression
530			_aIssued also as CD
653		4	_aBurkitt{u2019}s lymphoma
653		4	_aChildren
653		4	_aOutcome
700	0		_aEman Naguib Khorshed , _eSupervisor
700	0		_aHanafy Ahmed Hafez , _eSupervisor
700	0		_aRiham Abdelaziz Khedr , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAsmaa _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c76145 _d76145